Method for detecting mispairing and sample pollution conditions of whole-exome sequencing sample
By calculating the suballele frequency of SNP sites and setting sample standards, the problem of sample mismatch and contamination in whole exome sequencing is solved, and rapid and accurate detection is achieved, which improves detection accuracy and tumor mutations. Authenticity.
Patent Information
- Application Number
- CN202411114057.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-12
AI Technical Summary
In whole-exome sequencing, sample mismatch and sample contamination often lead to false and false positives in detection results, and it is difficult for the prior art to quickly and accurately identify and correct these problems.
By calculating the suballele frequency of SNP sites, setting sample mismatch and pollution standards, determining whether the sample is mismatched or contaminated, and calculating the contamination ratio, and using non-linked site screening and variation detection to achieve fast and accurate Test.
It realizes the rapid and accurate identification of sample mismatch and pollution, improves detection accuracy, can detect contamination as low as 1%, and improves the authenticity of system mutations in tumor patients.
Smart Images

Figure CN118932028A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of gene sequencing, and in particular to a method for detecting sample mismatch and sample contamination in whole exome sequencing. Background Art
[0002] Whole Exome Sequencing (WES) can selectively perform high-throughput sequencing on the coding region of the human genome. Compared with whole genome sequencing, it is widely used in clinical tumor detection due to its low cost, high efficiency and short cycle. Using WES technology to detect the gene mutation characteristics of tumors plays an important role in targeted drug use, immunotherapy program formulation and efficacy evaluation.
[0003] However, factors such as the disorder of the test sample number and the wrong sampling from the sample library can cause sample mismatch, resulting in two samples coming from different individuals. On the one hand, once a sample mismatch occurs, it is impossible to determine whether the sample comes from the tested patient, and subsequent test results are all wrong. On the other hand, in sample testing, samples need to go through the stages of collection, storage, transportation, preparation, and experimental operation, and samples will inevitably be contaminated or cross-contaminated to varying degrees. Sample contamination will mix the DNA of other individuals into the sample to be tested. Even a small degree of contamination will introduce low-abundance false mutations, making it difficult to identify whether it is derived from a real mutation in the sample to be tested, resulting in false positive test results. Therefore, it is very necessary to design a method for detecting sample mismatch and sample contamination in whole exome sequencing. Summary of the invention
[0004] The purpose of the present invention is to provide a method for detecting mismatches and contamination of whole exome sequencing samples, so as to realize the function of quickly and accurately identifying whether a WES sequencing sample is mismatched or contaminated, and to improve the accuracy of detection.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] A method for detecting mismatch and contamination of whole exome sequencing samples comprises the following steps:
[0007] The minor allele frequency of the SNP locus is obtained according to the WES sequencing samples; the WES sequencing samples include: the sample to be tested and the paired sample;
[0008] The sample mismatch standard was obtained based on the minor allele frequency;
[0009] Determine whether the WES sequencing sample is mismatched based on the sample mismatch criteria;
[0010] The sample contamination standard was obtained based on the minor allele frequency;
[0011] Determine whether the WES sequencing sample is contaminated according to the sample contamination standard. If so, calculate the contamination ratio.
[0012] Optionally, the minor allele frequency of the SNP site is obtained according to the WES sequencing sample, and the specific steps are as follows:
[0013] Screen WES sequencing samples for SNP sites within the population genome frequency range;
[0014] Select non-linked sites among SNP sites; the physical distance between non-linked sites is greater than 0.5M;
[0015] Minor allele frequencies were obtained based on unlinked loci.
[0016] Optionally, the minor allele frequency is obtained based on the unlinked loci, and the specific steps are as follows:
[0017] Compare the unlinked sites to the human reference genome to obtain a comparison file;
[0018] Sort the comparison files to obtain a sorted file;
[0019] Repeat labeling and quality correction are performed on the sequencing file to obtain a correction file;
[0020] Perform mutation detection on the correction file to obtain mutation abundance;
[0021] The minor allele frequency was obtained based on the mutation abundance.
[0022] Optionally, the sample mismatch criteria include: heterozygous loss ratio and homozygous loss ratio; homozygous is a SNP site with a minor allele frequency less than or equal to a first abundance threshold, and heterozygous is a SNP site with a minor allele frequency greater than the first abundance threshold.
[0023] Optionally, the calculation formula for the homozygous loss ratio is: homo.loss.ratio=N1 / N2; wherein, homo.loss.ratio is the homozygous loss ratio, N1 is the number of SNP sites that are homozygous in the paired sample and heterozygous in the sample to be tested, and N2 is the number of SNP sites that are homozygous in the paired sample; the calculation formula for the heterozygous loss ratio is: hete.loss.ratio=N3 / N4; wherein, hete.loss.ratio is the heterozygous loss ratio, N3 is the number of SNP sites that are heterozygous in the paired sample and homozygous in the sample to be tested, and N4 is the number of SNP sites that are heterozygous in the paired sample.
[0024] Optionally, whether the WES sequencing sample is mismatched is determined according to a sample mismatch standard, where the judgment standard is: when the homozygous loss ratio is greater than or equal to 20% and the heterozygous loss ratio is greater than or equal to 20%, the WES sequencing sample is determined to be a mismatched sample.
[0025] Optionally, sample contamination criteria include biasing the proportion for homozygotes.
[0026] Optionally, the calculation formula for the homozygous bias ratio is: homo.bias.ratio=N5 / N6; wherein, homo.bias.ratio is the homozygous bias ratio, N5 is the number of SNP sites whose minor allele frequency in the paired sample is less than or equal to the second abundance threshold and whose minor allele frequency in the sample to be tested is greater than the second abundance threshold, and N6 is the number of SNP sites whose minor allele frequency in the paired sample is less than or equal to the first abundance threshold.
[0027] Optionally, whether the WES sequencing sample is contaminated is determined according to a sample contamination standard, where the judgment standard is: when the homozygous deviation ratio is greater than or equal to 10%, the WES sequencing sample is determined to be a contaminated sample.
[0028] Optionally, the contamination ratio is the maximum value of the deviation of the mutation abundance at the homozygous offset site.
[0029] According to the specific embodiments provided by the present invention, the present invention discloses the following technical effects: the whole exome sequencing sample mismatch and sample contamination detection method provided by the present invention comprises: obtaining the minor allele frequency of the SNP site according to the WES sequencing sample; obtaining the sample mismatch standard according to the minor allele frequency; judging whether the WES sequencing sample is mismatched according to the sample mismatch standard; if not, obtaining the sample contamination standard according to the minor allele frequency; judging whether the WES sequencing sample is contaminated according to the sample contamination standard, and if so, calculating the contamination ratio. The method realizes the function of quickly and accurately identifying whether the WES sequencing sample is mismatched or contaminated, and improves the accuracy of the detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0031] Figure 1 This is a flow chart of a method for detecting sample mismatch and sample contamination in whole exome sequencing according to an embodiment of the present invention;
[0032] Figure 2A detailed flow chart of step 100 of an embodiment of the present invention;
[0033] Figure 3 This is a SNP mutation abundance distribution diagram of mismatched samples in an embodiment of the present invention;
[0034] Figure 4 This is the SNP mutation abundance distribution diagram of the 5% contaminated sample in the embodiment of the present invention;
[0035] Figure 5 This is a SNP mutation abundance distribution diagram of 30% contaminated samples in an embodiment of the present invention. DETAILED DESCRIPTION
[0036] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0037] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0038] like Figure 1 As shown, an embodiment of the present invention provides a method for detecting mismatch and sample contamination of whole exome sequencing samples, comprising the following steps:
[0039] Step 100: Obtain the minor allele frequency of the SNP site according to the WES sequencing sample; the WES sequencing sample includes: a sample to be tested and a paired sample; Figure 2 As shown, the specific implementation process of this step is:
[0040] Step 101: According to the detection range of WES sequencing, SNP sites with a population frequency in the range of 30% to 70% in the WBBC database are screened;
[0041] Specifically, the sample to be tested is the tumor tissue, cerebrospinal fluid, pleural effusion, lymph node or nucleic acid thereof of the subject; the paired sample is the adjacent cancer tissue, whole blood or oral exfoliated cells of the same subject.
[0042] Specifically, both the sample to be tested and the paired sample include homozygotes and heterozygotes. The homozygotes are SNP sites with a minor allele frequency less than or equal to the first abundance threshold, and the heterozygotes are SNP sites with a minor allele frequency greater than the first abundance threshold; the first abundance threshold ranges from 1% to 10%, and is 10% in this embodiment; homozygotes include wild type and mutant type.
[0043] Step 102: Select non-linked sites with a physical distance greater than 0.5M among the SNP sites; the number of non-linked sites selected can be all, 300 to 400, or less.
[0044] Step 103: Perform quality control analysis on the FASTQ sequence in the non-linked site to obtain a quality control sequence;
[0045] Specifically, quality control analysis includes: removing adapters, filtering out low-quality sequences, and excising low-quality base sequences.
[0046] Step 104: Use BWA software to compare the quality control sequence to the GRCh37 / hg19 human reference genome to form a SAM file;
[0047] Step 105: Sort the SAM file according to the Samtools software and the chromosome position of the SAM file to generate a BAM file and an index file;
[0048] Step 106: Perform PCR duplication labeling and quality correction on the BAM file and the index file respectively using GATK software to obtain a correction file;
[0049] Step 107: Perform SNP variation detection on the calibration file using Pisces software, and extract the mutation abundance of each SNP site based on the detection results;
[0050] Specifically, mutation abundance is the number of mutated sequences at a mutation site divided by the number of all sequences covering that site.
[0051] Step 108: Obtain the minor allele frequency according to the mutation abundance.
[0052] Specifically, when the mutation abundance is greater than 50%, the minor allele frequency is 100-mutation abundance, and when the mutation abundance is less than or equal to 50%, the minor allele frequency is the mutation abundance.
[0053] Step 200: Obtaining a sample mismatch standard according to the minor allele frequency;
[0054] Specifically, the sample mismatch criteria include: heterozygous loss ratio and homozygous loss ratio.
[0055] Specifically, the calculation formula for the homozygous loss ratio is: homo.loss.ratio=N1 / N2; wherein, homo.loss.ratio is the homozygous loss ratio, N1 is the number of SNP sites that are homozygous in the paired sample and heterozygous in the sample to be tested, and N2 is the number of SNP sites that are homozygous in the paired sample; the calculation formula for the heterozygous loss ratio is: hete.loss.ratio=N3 / N4; wherein, hete.loss.ratio is the heterozygous loss ratio, N3 is the number of SNP sites that are heterozygous in the paired sample and homozygous in the sample to be tested, and N4 is the number of SNP sites that are heterozygous in the paired sample.
[0056] Step 300: Determine whether the WES sequencing sample is mismatched according to the sample mismatch standard;
[0057] Specifically, the criteria for judging whether there is a mismatch are: when the homozygous loss ratio and the heterozygous loss ratio are both greater than or equal to 20%, the WES sequencing sample is determined to be a mismatched sample. Figure 3 shown.
[0058] Step 400: Obtaining a sample contamination standard according to the minor allele frequency;
[0059] Specifically, the sample contamination criterion is the homozygous bias ratio.
[0060] Specifically, the process of homozygous shift is: the mutation abundance of wild-type SNP is 0, the frequency of heterozygous mutation is 50%, and the mutation abundance of homozygous mutation is 100%. When a wild-type SNP is mixed with heterozygous or homozygous mutation, its mutation abundance will deviate from 0, and the greater the sample contamination, the greater the mutation abundance; when a homozygous mutation SNP is mixed with wild-type or heterozygous mutation, its mutation abundance will deviate from 100%, and the greater the sample contamination, the smaller the mutation abundance.
[0061] More specifically, the calculation formula for the homozygous bias ratio is: homo.bias.ratio=N5 / N6; wherein, homo.bias.ratio is the homozygous bias ratio, N5 is the number of SNP sites whose minor allele frequency in the paired sample is less than or equal to the second abundance threshold and whose minor allele frequency in the sample to be tested is greater than the second abundance threshold, and N6 is the number of SNP sites whose minor allele frequency in the paired sample is less than or equal to the first abundance threshold; the selection range of the second abundance threshold is 1% to 10%, and in this embodiment it is 1%.
[0062] Step 500: Determine whether the WES sequencing sample is contaminated according to the sample contamination standard, and if so, calculate the contamination ratio.
[0063] Specifically, the criterion for judging whether a WES sequencing sample is contaminated is: when the homozygous deviation ratio is greater than or equal to 10%, the WES sequencing sample is determined to be a contaminated sample.
[0064] Specifically, the contamination ratio is the maximum value of the deviation value of the homozygous offset site mutation abundance, and the calculation process is:
[0065] First, calculate the homozygous mutation abundance deviation value (homo.bias.vaf); when the SNP site of the paired sample is a homozygous mutation abundance less than 1%, homo.bias.vaf = mutation abundance; when the SNP site of the paired sample is a homozygous mutation abundance greater than or equal to 99%, homo.bias.vaf = 100-mutation abundance;
[0066] Secondly, the deviation values of homozygous mutation abundance were sorted from small to large, and abnormal extreme values were removed according to the interquartile range rule;
[0067] Finally, the maximum homozygous mutation abundance deviation value was taken as the contamination proportion of the sample.
[0068] Among them, the distribution of contaminated samples with contamination ratios of 5% and 30% are as follows: Figure 4 and Figure 5 shown.
[0069] The specific contents of specific embodiment 1 of the present invention are as follows:
[0070] As shown in Table 1, the samples to be tested and the paired samples of 10 pairs of paired real WES sample pairs were combined into 100 sample pairs and mismatch experiments were performed, of which 10 pairs were successfully paired and 90 pairs were mismatched samples. The homozygous deletion ratio and heterozygous deletion ratio of these 100 sample pairs were calculated respectively, and the minimum value, maximum value, mean and variance were obtained respectively. According to the preset threshold, when the homozygous loss ratio and the heterozygous loss ratio were both greater than or equal to 20%, the sample was determined as a mismatched sample. All 100 pairs of samples were correctly determined, with an accuracy rate of 100%.
[0071] Table 1 Summary of mismatch experiment results
[0072]
[0073] The specific contents of specific embodiment 2 of the present invention are as follows:
[0074] As shown in Table 2, for the real WES sequencing samples A-tumor, A-normal and B, the FASTQ sequence of sample B was extracted according to a certain ratio and merged into the FASTQ sequence of sample A-tumor, generating 10 contaminated sample Mixes with contamination rates of 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30% and 40%, respectively. The homozygous shift ratio and sample contamination ratio of the 10 contaminated samples in the paired sample A-normal were calculated respectively.
[0075] Table 2 Calculation results of contaminated samples
[0076]
[0077]
[0078] The specific contents of specific embodiment 3 of the present invention are as follows:
[0079] As shown in Table 3, two tumor DNAs from different subjects were mixed in different gradients, with mixing ratios of 1%, 5%, 10%, 20%, 30%, 40% and 50% to obtain contaminated samples Mix. The contaminated samples Mix and 10 pairs of uncontaminated samples N were tested respectively.
[0080] Table 3 Summary of test results
[0081]
[0082]
[0083] The beneficial effects of the present invention are as follows:
[0084] 1) The present invention can quickly and accurately identify whether a WES sequencing sample is mismatched or contaminated, and can detect contamination as low as 1%, thereby improving the accuracy of the detection;
[0085] 2) The computer can be operated faster by reducing the number of non-linked sites, thereby improving detection efficiency;
[0086] 3) The method of the present invention improves the authenticity of detecting mutations in tumor patient systems.
[0087] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.
[0088] The present invention uses specific examples to illustrate the principles and implementation methods of the present invention. The above examples are only used to help understand the method and core ideas of the present invention. At the same time, for those skilled in the art, according to the ideas of the present invention, there will be changes in the specific implementation methods and application scope. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A method for detecting sample mismatch and sample contamination in whole exome sequencing, characterized in that: The steps include: Obtaining the minor allele frequency of the SNP site according to the WES sequencing sample; the WES sequencing sample includes: a sample to be tested and a paired sample; Obtaining a sample mismatch standard according to the minor allele frequency; Determine whether the WES sequencing sample is mismatched according to the sample mismatch standard; Obtaining a sample contamination standard based on the minor allele frequency; Whether the WES sequencing sample is contaminated is determined according to the sample contamination standard, and if so, the contamination ratio is calculated.
2. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 1, characterized in that: The minor allele frequency of the SNP locus is obtained according to the WES sequencing sample. The specific steps are as follows: Screening the SNP sites of the WES sequencing sample within the frequency range of the human genome; Selecting non-linked sites among the SNP sites; the physical distance between the non-linked sites is greater than 0.5M; The minor allele frequency is obtained based on the unlinked loci.
3. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 2, characterized in that: The minor allele frequency is obtained according to the unlinked loci, and the specific steps are: Comparing the unlinked sites to a human reference genome to obtain a comparison file; Sorting the comparison files to obtain a sorted file; Performing repeated marking and quality correction on the sorting file to obtain a correction file; Performing mutation detection on the correction file to obtain mutation abundance; The minor allele frequency is obtained according to the mutation abundance.
4. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 1, characterized in that: The sample mismatch standard includes: heterozygote loss ratio and homozygote loss ratio; the homozygote is a SNP site whose minor allele frequency is less than or equal to the first abundance threshold, and the heterozygote is a SNP site whose minor allele frequency is greater than the first abundance threshold.
5. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 4, characterized in that: The calculation formula for the homozygous loss ratio is: homo.loss.ratio=N1 / N2; wherein, homo.loss.ratio is the homozygous loss ratio, N1 is the number of SNP sites that are homozygous in the paired sample and heterozygous in the sample to be tested, and N2 is the number of SNP sites that are homozygous in the paired sample; the calculation formula for the heterozygous loss ratio is: hete.loss.ratio=N3 / N4; wherein, hete.loss.ratio is the heterozygous loss ratio, N3 is the number of SNP sites that are heterozygous in the paired sample and homozygous in the sample to be tested, and N4 is the number of SNP sites that are heterozygous in the paired sample.
6. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 4, characterized in that: Whether the WES sequencing sample is mismatched is determined according to the sample mismatch standard, and the judgment standard is: when the homozygous loss ratio is greater than or equal to 20% and the heterozygous loss ratio is greater than or equal to 20%, the WES sequencing sample is determined as a mismatched sample.
7. The method for detecting sample mismatch and sample contamination in whole exome sequencing according to claim 1, characterized in that: The sample contamination standard is the homozygous deviation ratio.
8. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 7, characterized in that: The calculation formula for the homozygous bias ratio is: homo.bias.ratio=N5 / N6; wherein, homo.bias.ratio is the homozygous bias ratio, N5 is the number of SNP sites in which the minor allele frequency in the paired sample is less than or equal to the second abundance threshold and the minor allele frequency in the sample to be tested is greater than the second abundance threshold, and N6 is the number of SNP sites in which the minor allele frequency in the paired sample is less than or equal to the first abundance threshold.
9. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 7, characterized in that: Whether the WES sequencing sample is contaminated is determined according to the sample contamination standard, and the judgment standard is: when the homozygous deviation ratio is greater than or equal to 10%, the WES sequencing sample is determined to be a contaminated sample.
10. The method for detecting mismatch and contamination of whole exome sequencing samples according to claim 1, characterized in that: The contamination ratio is the maximum value of the deviation value of the mutation abundance of the homozygous offset site.
Citation Information
Patent Citations
Genotype detection method, sample pollution detection method, device, equipment and medium
CN115035950A
Method and device for detecting sample contamination and identifying sample mismatch
CN116312779A
Method for determining proportion of donor source cfdna in receptor cfdna sample
WO2017045654A1
